Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;36(1):157-159.
doi: 10.1007/s40620-022-01344-7. Epub 2022 May 14.

Assay-related differences in SuPAR levels: implications for measurement and data interpretation

Alexi Vasbinder  1 , Laura Marie Raffield  2 , Yan Gao  3 , Gunnar Engstrom  4 , Arshed Ali Quyyumi  5 , Alexander Paul Reiner  6 , Jochen Reiser  7 , Salim Salim Hayek  8
Affiliations

Assay-related differences in SuPAR levels: implications for measurement and data interpretation

Alexi Vasbinder et al. J Nephrol. 2023 Jan.
No abstract available

Keywords: Olink; Quantikine; SOMAScan; Soluble urokinase plasminogen activator receptor; Virogates; suPARnostic.

PubMed Disclaimer

Conflict of interest statement

SSH and JR are scientific advisory board members of Walden Biosciences Inc.

References

    1. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373(20):1916–1925. doi: 10.1056/NEJMoa1506362. - DOI - PMC - PubMed
    1. Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, et al. Comparison of proteomic assessment methods in multiple cohort studies. Proteomics. 2020;20(12):e1900278. doi: 10.1002/pmic.201900278. - DOI - PMC - PubMed
    1. Joshi A, Mayr M. In aptamers they trust: the caveats of the SOMAscan biomarker discovery platform from SomaLogic. Circulation. 2018;138(22):2482–2485. doi: 10.1161/CIRCULATIONAHA.118.036823. - DOI - PMC - PubMed
    1. Winnicki W, Sunder-Plassmann G, Sengolge G, Handisurya A, Herkner H, Kornauth C, et al. Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in Focal segmental glomerulosclerosis and impact of detection method. Sci Rep. 2019;9(1):13783. doi: 10.1038/s41598-019-50405-8. - DOI - PMC - PubMed
    1. Abraham AG, Xu Y, Roem JL, Greenberg JH, Weidemann DK, Sabbisetti VS, et al. Variability in CKD biomarker studies: suPAR and kidney disease progression in the chronic kidney disease in children (CKiD) study. Kidney Med. 2021;5(3):P712–P721. doi: 10.1016/j.xkme.2021.04.007. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources